Biogen (BIIB) stock price, revenue, and financials

Biogen market cap is $40.6 b, and annual revenue was $11.45 b in FY 2016

$40.6 B

BIIB Mkt cap, 18-Oct-2019

$2.8 B

Biogen Revenue Q1, 2017
Biogen Net income (Q1, 2017)747.5 M
Biogen EBIT (Q1, 2017)1 B
Biogen Cash, 31-Mar-2017924 M

Biogen Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9b9.7b10.8b11.4b

Revenue growth, %

40%11%6%

R&D expense

2.0b

General and administrative expense

1.9b

Operating expense total

3.9b

EBIT

4.9b5.2b

EBIT margin, %

45%45%

Income tax expense

1.2b1.2b

Net Income

1.9b2.9b3.6b3.7b

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4b2.5b2.6b2.6b2.8b2.7b2.9b3.0b2.8b

R&D expense

447.3m417.2m460.5m490.7m519.9m437.3m473.1m529.0m423.4m

General and administrative expense

576.6m570.4m560.4m491.9m477.8m497.3m492.4m462.7m499.1m

Operating expense total

1.0b987.6m1.0b982.6m997.7m934.6m965.5m991.7m922.5m

EBIT

988.7m1.2b1.1b1.2b1.4b1.4b1.5b1.4b1.0b

EBIT margin, %

41%46%44%48%49%51%50%48%36%

Income tax expense

268.5m274.8m281.9m292.5m330.1m356.4m353.6m337.0m239.2m

Net Income

723.1m856.1m820.2m924.8m1.0b969.2m1.0b1.0b747.5m

Biogen Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6m1.2b1.3b2.3b

Accounts Receivable

824.4m1.3b1.2b1.4b

Inventories

659.0m804.0m893.4m1.0b

Current Assets

3.2b4.7b6.7b8.7b

PP&E

1.8b1.8b2.2b2.5b

Goodwill

1.2b1.8b2.7b3.7b

Total Assets

11.9b14.3b19.5b22.9b

Accounts Payable

219.9m229.2m267.4m279.8m

Short-term debt

582.1m

Current Liabilities

1.8b2.2b2.6b3.4b

Long-term debt

582.1m

Total Debt

1.2b

Total Liabilities

10.7b

Additional Paid-in Capital

4.0b4.2b

Retained Earnings

6.3b9.3b12.2b15.1b

Total Equity

8.6b10.8b9.4b12.1b

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.3 x2.1 x1.9 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2m1.2b1.5b1.3b4.1b1.1b1.4b2.1b924.0m

Accounts Receivable

1.0b1.1b1.4b1.3b1.3b1.4b1.3b1.5b1.5b

Inventories

715.9m753.1m825.3m865.7m918.9m964.6m996.4m1.0b921.6m

Current Assets

3.9b4.4b5.3b5.6b9.3b7.2b7.4b8.1b6.9b

PP&E

1.8b1.7b1.7b1.8b2.0b2.3b2.3b2.4b2.6b

Goodwill

1.4b1.5b1.8b2.2b2.4b2.9b3.2b3.4b3.6b

Total Assets

12.9b13.7b15.2b16.8b20.7b20.7b21.5b22.1b21.2b

Accounts Payable

224.9m233.6m236.1m282.7m251.2m271.3m225.9m274.0m316.4m

Short-term debt

586.1m584.0m580.7m576.2m

Current Liabilities

1.9b1.9b1.9b2.6b2.6b2.8b2.5b2.5b3.0b

Long-term debt

586.1m584.0m580.7m576.2m

Additional Paid-in Capital

4.1b4.2b4.2b4.3b1.3b18.4m69.1m

Retained Earnings

7.5b8.4b10.1b11.0b12.0b13.2b14.2b15.0b14.8b

Total Equity

9.6b10.4b11.7b12.6b10.6b10.3b11.4b12.1b11.5b

Financial Leverage

1.4 x1.3 x1.3 x1.3 x2 x2 x1.9 x1.8 x1.8 x

Biogen Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9b2.9b3.6b3.7b

Depreciation and Amortization

688.2m600.4m682.7m

Accounts Receivable

(130.0m)(510.0m)29.0m(241.4m)

Inventories

(240.0m)(190.0m)(170.0m)(165.6m)

Purchases of PP&E

(246.3m)(287.8m)(643.0m)(616.1m)

Cash From Investing Activities

(1.6b)(1.5b)(4.6b)(2.5b)

Cash From Financing Activities

(716.5m)(755.9m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1m856.1m820.2m924.8m1.0b969.2m1.0b1.0b747.5m

Accounts Receivable

1.3b1.3b1.4b1.3b1.5b1.5b

Inventories

865.7m918.9m964.6m996.4m1.0b921.6m

Accounts Payable

282.7m251.2m271.3m225.9m274.0m316.4m

Biogen Ratios

USDY, 2017

Financial Leverage

1.8 x

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
FY, 2016

Phase I Trials Products

4

Phase II Trials Products

10

Phase III Trials Products

2

Training Provided, no. of people

40 k

Biogen Employee Rating

3.6983 votes
Culture & Values
3.6
Work/Life Balance
3.5
Senior Management
2.8
Salary & Benefits
4.1
Career Opportunities
3.2
Source